Amgen Inc. (AMGN)
Forget Eli Lilly: 3 Biotech Stocks to Buy Instead
Amgen is much cheaper than Eli Lilly. Vertex Pharmaceuticals has several major growth drivers.
1 Dividend Growth Stock to Buy and Hold for 10 Years
Amgen has maintained an impressive dividend streak over the past decade. The company's business should allow it to maintain this momentum for a while.
Jefferies Red-Hot Summer Top Stock Picks Include 5 Blue Chip Dividend Giants
24/7 Wall St. Insights Jefferies is one of Wall Street's fastest-growing firms.
Can Amgen Stock Keep Trouncing the S&P 500?
Amgen has been one of the best performing stocks since its IPO in 1983. Over the prior 12 months, the biotech's shares have continued this rich tradition.
Why Amgen (AMGN) Outpaced the Stock Market Today
Amgen (AMGN) closed at $319.31 in the latest trading session, marking a +0.36% move from the prior day.
Where Will Amgen Be in 5 Years?
The drugmaker has a promising weight-loss drug in clinical trials, MariTide, which could be a game changer. Recent acquisitions have bolstered Amgen's portfolio, which could pave the way for even more growth.
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
Biotech stocks operate under a core ethos. While there's been much talk about financially viable sectors – from tech to cryptocurrencies to even precious metals – when you think about it, nothing is more valuable than one's health.
Amgen: You Haven't Seen Anything Yet
Amgen continues to delight investors with the growth in sales of its key blockbusters and the expansion of its portfolio of medications. In mid-June, Amgen pleased investors by announcing that the FDA had approved Blincyto to treat certain patients with B-precursor acute lymphoblastic leukemia. Ten days earlier, the company released promising results from a Phase 3 clinical trial evaluating Uplizna's efficacy in treating Immunoglobulin G4-related disease.
Amgen's (AMGN) Blincyto Gets FDA Nod for Consolidation Treatment
Amgen's (AMGN) Blincyto is now approved for the treatment of adult and pediatric patients one month and older with Philadelphia chromosome-negative B-ALL in the consolidation phase, regardless of MRD status.
3 Stocks to Buy as Ozempic Surges in Popularity
Ozempic and Wegovy (semaglutide for diabetes and weight loss, respectively) are popular weight-loss drugs that have taken the world by storm. Indeed, the craze is showing no signs of slowing down as more supply of GLP-1 receptor agonists comes online to meet blistering demand.
Amgen Inc. (AMGN) Goldman Sachs 45th Annual Global Healthcare Conference Transcript
Amgen Inc. (NASDAQ:AMGN ) Goldman Sachs 45th Annual Global Healthcare Conference June 10, 2024 9:20 AM ET Company Participants James E. Bradner – EVP of Research and Development & Chief Scientific Officer Peter H.
